Cargando…
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis
OBJECTIVE: During rheumatoid arthritis (RA), the angiogenic processes, occurring with pannus-formation, may be a therapeutic target. JAK/STAT-pathway may play a role and the aim of this work was to investigate the inhibiting role of a JAK-inhibitor, tofacitinib, on the angiogenic mechanisms occurrin...
Autores principales: | Di Benedetto, Paola, Ruscitti, Piero, Berardicurti, Onorina, Panzera, Noemi, Grazia, Nicolò, Di Vito Nolfi, Mauro, Di Francesco, Barbara, Navarini, Luca, Maurizi, Antonio, Rucci, Nadia, Teti, Anna Maria, Zazzeroni, Francesca, Guggino, Giuliana, Ciccia, Francesco, Dolo, Vincenza, Alesse, Edoardo, Cipriani, Paola, Giacomelli, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364029/ https://www.ncbi.nlm.nih.gov/pubmed/34391476 http://dx.doi.org/10.1186/s13075-021-02587-8 |
Ejemplares similares
-
Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6
por: Ruscitti, Piero, et al.
Publicado: (2022) -
Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling
por: Di Benedetto, Paola, et al.
Publicado: (2019) -
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy
por: Di Benedetto, Paola, et al.
Publicado: (2018) -
Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study
por: Ruscitti, Piero, et al.
Publicado: (2019) -
The Role of IL-1β in the Bone Loss during Rheumatic Diseases
por: Ruscitti, Piero, et al.
Publicado: (2015)